Display options
Cite
Aghemo A, Rumi MG, Monico S, et al. Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. Hepat Mon. 2011;11(11):918-24doi: 10.5812/kowsar.1735143X.733.
Aghemo, A., Rumi, M. G., Monico, S., Banderali, M., Russo, A., Ottaviani, F., Vigano, M., D'Ambrosio, R., & Colombo, M. (2011). Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. Hepatitis monthly, 11(11), 918-24. https://doi.org/10.5812/kowsar.1735143X.733
Aghemo, Alessio, et al. "Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients." Hepatitis monthly vol. 11,11 (2011): 918-24. doi: https://doi.org/10.5812/kowsar.1735143X.733
Aghemo A, Rumi MG, Monico S, Banderali M, Russo A, Ottaviani F, Vigano M, D'Ambrosio R, Colombo M. Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. Hepat Mon. 2011 Nov;11(11):918-24. doi: 10.5812/kowsar.1735143X.733. Epub 2011 Nov 30. PMID: 22308157; PMCID: PMC3269061.
Copy Download .nbib Format: NLM
Share it on

Hepat Mon. 2011 Nov;11(11):918-24. doi: 10.5812/kowsar.1735143X.733. Epub 2011 Nov 30.

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients.

Hepatitis monthly

Alessio Aghemo, Maria Grazia Rumi, Sara Monico, Matteo Banderali, Antonio Russo, Francesco Ottaviani, Mauro Vigano, Roberta D'Ambrosio, Massimo Colombo

Affiliations

  1. A. M. Migliavacca Center for Liver Disease First, Division of Gastroenterology, IRCCS Fondazione Ca' Granda Hospital, University of Milan, Milan, Italy.

PMID: 22308157 PMCID: PMC3269061 DOI: 10.5812/kowsar.1735143X.733

Abstract

BACKGROUND: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment.

OBJECTIVES: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy.

PATIENTS AND METHODS: Thirty-one naïve patients with chronic hepatitis C consecutively received PegIFN-α2a (180 μg/week) plus Rbv (800-1200 mg/day). The controls were 10 patients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment and follow-up, all patients underwent basal and masticatory stimulated sialometry,otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively assess symptoms of oral dryness.

RESULTS: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87% vs. 40%, P = 0.006) reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients on monotherapy had ORL signs of salivary gland hypofunction (97% vs. 20%, P < 0.0001).Mean basal (A) and stimulated (B) salivary flow rates (mL/min) progressively decreased during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P < 0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 following PegIFN/Rbv treatment, salivary flow rates were similar to baseline (A, 0.53 at the end of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary function was unaffected in monotherapy patients.

CONCLUSIONS: Rbv causes salivary gland hypofunction in hepatitis C patients receiving PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment.

Keywords: Hepatitis B; Hepatitis C; Peginterferon Alfa-2a; Ribavirin; Salivary Glands

References

  1. Antivir Ther. 2006;11(6):797-802 - PubMed
  2. Ann Rheum Dis. 2001 Dec;60(12):1110-6 - PubMed
  3. N Engl J Med. 2004 Sep 16;351(12):1206-17 - PubMed
  4. Ann N Y Acad Sci. 1998 Apr 15;842:132-7 - PubMed
  5. Hepatology. 2011 May;53(5):1742-51 - PubMed
  6. N Engl J Med. 2011 Mar 31;364(13):1195-206 - PubMed
  7. Lancet. 2001 Sep 22;358(9286):958-65 - PubMed
  8. J Hepatol. 2010 May;52(5):652-7 - PubMed
  9. Antivir Ther. 2007;12(7):1033-40 - PubMed
  10. Hepatology. 2002 Nov;36(5 Suppl 1):S35-46 - PubMed
  11. Hepatology. 2003 Sep;38(3):645-52 - PubMed
  12. Nature. 2005 Aug 18;436(7053):967-72 - PubMed
  13. Hepatology. 2002 Nov;36(5 Suppl 1):S237-44 - PubMed
  14. Oral Dis. 2004 Mar;10(2):75-80 - PubMed
  15. Hepatology. 1997 Sep;26(3 Suppl 1):112S-121S - PubMed
  16. Gut. 2004 Jan;53(1):130-5 - PubMed
  17. J Hepatol. 1995 Jun;22(6):696-9 - PubMed
  18. N Engl J Med. 2009 Apr 30;360(18):1839-50 - PubMed
  19. Lancet. 2004 May 22;363(9422):1728-31 - PubMed
  20. N Engl J Med. 2009 Apr 30;360(18):1827-38 - PubMed
  21. Hepatology. 2007 Mar;45(3):579-87 - PubMed
  22. Lancet. 2010 Aug 28;376(9742):705-16 - PubMed
  23. Strahlenther Onkol. 2006 Jun;182(6):336-41 - PubMed
  24. Ann Rheum Dis. 2002 Feb;61(2):137-44 - PubMed
  25. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Jun;95(6):693-8 - PubMed

Publication Types